Letter from the Editor
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2012-07-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Online Access: | https://www.tandfonline.com/doi/10.4161/hv.21441 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850248602982547456 |
|---|---|
| author | Ronald W. Ellis Eva M. Riedmann |
| author_facet | Ronald W. Ellis Eva M. Riedmann |
| author_sort | Ronald W. Ellis |
| collection | DOAJ |
| format | Article |
| id | doaj-art-c2b2f83ff31143959fc4a53a6f58b38c |
| institution | OA Journals |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2012-07-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-c2b2f83ff31143959fc4a53a6f58b38c2025-08-20T01:58:41ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2012-07-018784584510.4161/hv.21441Letter from the EditorRonald W. Ellis0Eva M. Riedmann1Senior Vice President R&D and Chief Technology Officer; NasVax, Ltd.; Ness Ziona, IsraelAcquisitions Editor; Landes Bioscience; Vienna, Austriahttps://www.tandfonline.com/doi/10.4161/hv.21441 |
| spellingShingle | Ronald W. Ellis Eva M. Riedmann Letter from the Editor Human Vaccines & Immunotherapeutics |
| title | Letter from the Editor |
| title_full | Letter from the Editor |
| title_fullStr | Letter from the Editor |
| title_full_unstemmed | Letter from the Editor |
| title_short | Letter from the Editor |
| title_sort | letter from the editor |
| url | https://www.tandfonline.com/doi/10.4161/hv.21441 |
| work_keys_str_mv | AT ronaldwellis letterfromtheeditor AT evamriedmann letterfromtheeditor |